{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:39:18Z","timestamp":1791272358397,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.bbmt.2015.04.005","type":"journal-article","created":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T16:04:31Z","timestamp":1428681871000},"page":"1437-1444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors"],"prefix":"10.1016","volume":"21","author":[{"given":"Anish P.","family":"Nair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raewyn C.","family":"Broady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna E.","family":"Hogge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia L.","family":"Toze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen H.","family":"Nantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryse M.","family":"Power","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Nevill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Abou Mourad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujaatha","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina S.","family":"Gerrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna L.","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2015.04.005_bib1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2015.04.005_bib2","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.04.005_bib3","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.04.005_bib4","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.04.005_bib5","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.04.005_bib6","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.04.005_bib7","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.04.005_bib8","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.04.005_bib9","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","article-title":"Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia","volume":"112","author":"Lee","year":"2008","journal-title":"Blood"},{"issue":"2 Suppl 2","key":"10.1016\/j.bbmt.2015.04.005_bib10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/shem.2003.50044","article-title":"Molecular monitoring of chronic myeloid leukemia","volume":"40","author":"Hughes","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1016\/j.bbmt.2015.04.005_bib11","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1046\/j.1365-2141.1998.01030.x","article-title":"Bone marrow transplantation for adults with acute leukaemia and 11q23 chromosomal abnormalities","volume":"103","author":"Forrest","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2015.04.005_bib12","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.04.005_bib13","first-page":"247","article-title":"Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry","volume":"4","author":"Atkinson","year":"1989","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.04.005_bib14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2015.04.005_bib15","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.bmt.1703260","article-title":"Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis","volume":"28","author":"Klein","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.04.005_bib16","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/sim.1070","article-title":"Non-parametric confidence interval estimation for competing risks analysis: application to contraceptive data","volume":"21","author":"Choudhury","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.bbmt.2015.04.005_bib17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J\u00a0R Stat Soc B"},{"key":"10.1016\/j.bbmt.2015.04.005_bib18","doi-asserted-by":"crossref","unstructured":"Beyersmann J, Allignol A, Schumacher M. Competing risks and multistate models in R Springer, Use R,\u00a02012.","DOI":"10.1007\/978-1-4614-2035-4"},{"key":"10.1016\/j.bbmt.2015.04.005_bib19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0140-6736(82)92737-4","article-title":"Successful allogeneic bone-marrow transplantation for patients in the accelerated phase of chronic granulocytic leukaemia","volume":"2","author":"McGlave","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2015.04.005_bib20","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","article-title":"Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"352","author":"Gratwohl","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2015.04.005_bib21","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","article-title":"Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV","volume":"115","author":"Saussele","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.04.005_bib22","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00277-012-1650-8","article-title":"Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"92","author":"Oyekunle","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2015.04.005_bib23","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1182\/blood-2010-08-302679","article-title":"Results of allogeneic hematopoietic stem call transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations","volume":"117","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.04.005_bib24","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1182\/blood-2006-06-031682","article-title":"The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia","volume":"109","author":"Oehler","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.04.005_bib25","first-page":"452","article-title":"The effect of prior exposure to imatinib on transplant-related mortality","volume":"91","author":"Deininger","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2015.04.005_bib26","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.04.005_bib27","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood-2004-09-3544","article-title":"Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT","volume":"106","author":"Crawley","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.04.005_bib28","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1182\/blood-2012-02-409763","article-title":"Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era","volume":"119","author":"Warlick","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.04.005_bib29","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood.V98.7.2043","article-title":"Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age","volume":"98","author":"Kollman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.04.005_bib30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1179\/1607845413Y.0000000100","article-title":"Prognostic factors for outcomes of allogeneic stem cell transplantation in chronic phase chronic myeloid leukemia in the era of tyrosine kinase inhibitors","volume":"19","author":"Lee","year":"2014","journal-title":"Hematology"},{"key":"10.1016\/j.bbmt.2015.04.005_bib31","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bbmt.2009.11.026","article-title":"Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Wright","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.04.005_bib32","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N\u00a0Engl J Med"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115002499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115002499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:50:36Z","timestamp":1761058236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879115002499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S1083879115002499"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.04.005","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}